G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
We are encouraged by these preliminary results and look forward to clarifying the potential immune enhancing effects of COSELA in the tumor microenvironment.
- We are encouraged by these preliminary results and look forward to clarifying the potential immune enhancing effects of COSELA in the tumor microenvironment.
- ( poster )
In the United States, approximately 30,000 small cell lung cancer patients are treated annually. - SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers.
- G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.